Indicator full name: Incidence of female breast cancer per 100 000
Unit: cases per 100 000 population
- Country (COUNTRY)
- Supranational group of countries (COUNTRY_GRP)
- Sex (SEX)
- Year of measure (YEAR)
Years data is available: 1970—2016
Last updated: 17 October 2019
- WHO European Region
- Members of the European Union
- Members of the EU before May 2004 (EU15)
- Members of the EU after May 2004 (EU13)
- Commonwealth of Independent States
- Central Asian Republics Information Network members (CARINFONET)
- South-eastern Europe Health Network members (SEEHN)
- Nordic countries
- Small countries
The following abbreviations are used in the indicator titles:
Indicator code: E100601.F This indicator shares the definition with the parent indicator \"Number of new cases of female breast cancer\".
Number of female patients with newly diagnosed cancer of the breast (ICD-9: 174 or ICD-10: C50) during the given calendar year._
Data collected annually, reference period: 31 December.
A Viennese clinical study group collected data on breast cancer cases diagnosed in 2007, not only in
hospitals - who are legally oblidged to report all cases tot he Austrian national Register-, but
also from other registered ambulances and doctors. Statistics Austria was provided with these data,
which caused a singular peak in that particular year of disgnoses.
were incomplete and should be used with caution.
Public Health Institute of Republic of Srpska. Department for social medicine with health
organization and health economics. Law on Health Evidence and Statistical Research in Health. Annual
report of health facilities
Department for Health of Brcko District
Certificate Only are also included in all years (1998-2007).
Data from 1990 updated.
The sharp increase in year 2009 is caused by the introduction of a breast cancer-screening
Data have been updated on the basis of the Regisrtry?s database in January 2016.
Institute for Health and Welfare).
Source: Cancer Register, THL (National Institute for Health and Welfare) / Cancer Organizations.
par cancer en France entre 1980 et 2012
Due to reform in 2011, the data may show inconsistency.
http://www.krebsdaten.de or http://www.rki.de
Coverage: Data contain the estimated number of all newly diagnosed cancer cases of women in Germany
coded with ICD-10 C50 (Malignant neoplasm of breast) during the given calendar year.
Estimation method: The population-based cancer registries in each German federal state transfer data
to the German Centre for Cancer Registry Data (ZfKD), as required by the Federal Cancer Registry
Data Act (Bundeskrebsregisterdatengesetz). These data are combined, quality-checked, analysed and
At the moment reliable data on cancer incidence and survival are not available for all federal
states. Therefore, the ZfKD estimates new diagnosis, prevalence and survival rates for Germany in
addition to estimating the completeness of data capture in the individual registries. The basic
principle is that the data are first checked for registration completeness and, upon meeting
pre-defined criteria, are then used for the calculation of the various statistics.
The value of population-based cancer data vitally depends on the completeness of the capture of all
newly diagnosed cancer cases. Since 2009 in all federal states there has been comprehensive
geographical epidemiological cancer registration and great advances have been achieved. But the
situation in the individual states is very heterogeneous: continuous, state-wide registration was
commenced between 1967 (Saarland) and 2009 (Baden-Wurttemberg). The ZfKD consequently regularly
estimates the degree of completeness for the population-based cancer registries.
The basis for this evaluation is the ratio of incidence to mortality (M/I-Index), an internationally
commonly used indicator. It is assumed here that diagnosis and survival prospects of cancer patients
within Germany do not differ fundamentally and that regionally differing cancer risks can thus be
approximated by official cause of death statistics. Using the M/I-Index of a reference registry that
has been assessed as being complete along with the cancer mortality at a region whose completeness
is to be assessed, it is possible to estimate the expected cancer incidence in that region and
compare it with the number of cases actually registered.
According to the current evaluation, for the year 2012, twelve federal states have already reached
an estimated completeness level of at least 90%, seven federal states have reached over 95%
Using the data of the epidemiological cancer registries in Germany as a basis, the ZfKD estimates
the number of all newly diagnosed cancer cases each year. The results of the completeness assessment
form the basis of this estimation. The annual number of incident cases for each localization arises
from the summation of the cases from the ?complete? registries (estimated capture rate of at least
90%) and the expected incidence from the completeness assessment for those federal states that are
either deemed to be incomplete or for which no data is available.
Break in time series: The modification of the procedure to estimate completeness required the
adaption of the methods for estimating incidence. One of the requirements places on the new method
was to enable a smooth transition from ?estimating? to ?counting? the annual number of incident
cases in Germany while continuing to allow an assessment of trends over time. Since the new methods
of estimation for both completeness and incidence can only be used in this form from 1999 onwards,
the results of earlier estimates are not directly comparable to the current ones for methodological
Note: Benign tumours are rarely registered in the NCR. Some data from 1999 were recorded as year
2000. Correction of the data has only partially taken place. Therefore, there is a higher case
number in 2000. Data for the number of metastatic tumours with codes C77-C79 have been left out.
Note: From 2002 the data is shown as a 3-year average in order to minimize the random fluctuations
due to the small population of Iceland.
Centro Nazionale di Epidemiologia Sorveglianza e Prevenzione della Salute (ISS, CNESPS). Estimates
were obtained with the MIAMOD methodology using cancer-specific data on mortality 1970-2002
(Official National Statistics - ISTAT) and survival of patients diagnosed in 1985-2002 (Italian
Network of Cancer Registries - AIRTUM). The MIAMOD method has been applied to obtain forecasts from
2003 onwards . The estimates were obtained separately by sex for the 20 Italian regions. National
estimates were derived by summing up the regional estimates. All estimates are referred to age
group 0-99 years. For further details see: Rossi S, Capocaccia R, De Angelis R and Gatta G (Eds).
Cancer Burden in Italian Regions. Tumori 2013; 99 (3): pp. 269-439
data source is the Register of Patients with Particular Diseases.
Note: From 2011 the incidence is increasing because a screening programme for early detection of
female breast cancer has been initiated. Also, there is an improved registration practice regarding
new cases of cancer.
pathologique, de cytologie clinique et d'hematologie. Annual report edited by the association
\Registre morphologique des tumeurs au Grand-Duche
Pathology labs., Autopsy reports, National Mortality Register and Notification.
National Center for Statistics and Informatics in Public Health.
Break in time series:
2014: since year 2014, data from private sector included.
Coverage: complete from 2007 onwards. Up to 2007 data do not cover one NUTS level-2 Region
(Vojvodina) that is approximately 30% of population (according Census 2011 data). Decreasing of
number of new cases starting from 2012 onwards indicates underreporting by health institutions.
Methodology (definition): Number of all newly diagnosed breast cancers (ICD-9: 174 or ICD-10: C50)
during the given calendar year.
The Swedish Cancer Register (NBHW)
Online Database: http://www.socialstyrelsen.se/statistics/statisticaldatabase/cancerÿ
See the general documentation for variable 991051.
Icd7: 170 Breast
Registration (NICER) based on the Cancer Registries of Geneva (since 1970), Vaud and Neuchatel
(since 1974), Zurich (1980-2011), St. Gallen-Appenzell (since 1980), Basel-Stadt and
Basel-Landschaft (1981-2009), Valais and Graubunden (since 1989), Glarus (Since 1992), Ticino (Since
1996), Jura (since 2005), Fribourg (since 2006), Lucerne (since 2010), Nidwalden, Obwalden, Uri and
Zug (since 2011).
Coverage: extrapolation based on registered areas covering from 41% of the population in 1980 to 65%
Deviation from the definition:
Estimation method: The extrapolation is based on language regions, for detailed information please
refer to the Federal Statistical Office?s Cancer Epidemiology website.
with cancer?, 5 ?Report on morbidity?, 025-2/y ?Statistical card? and 090-1/y ?Notification of
patients with newly diagnosed malignancy?.
Northern Ireland - Northern Ireland Cancer Registry.
Scotland - Scottish Cancer Registry, NHS National Services Scotland, Information Services
Wales - Welsh Cancer Intelligence and Surveillance Unit.
Coverage: (In October 2013) Scotland revises their time series data due to the dynamic nature of
Deviation from the Definition: None
Break in Time Series:
2010 - All data is financial year data with the exception of Scotland and Northern Ireland whose
data is calendar year.
Estimate: 2014 data from Scotland is unavailable so the 2013 figure has been used as an estimate